Oncosil Medical

Oncosil Medical Debt

The Debt of Oncosil Medical (OSL.AX) as of Oct 28, 2026 is 14,782.00 AUD. In the previous year, Debt was 69,915.00 AUD — a change of -78.86% (lower).

Debt

14,782.00AUD

YoY

-78.86%

Last updated:

In 2026, Oncosil Medical's total debt was 14,782.00 AUD, a -78.86% change from the 69,915.00 AUD total debt recorded in the previous year.

The Oncosil Medical Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt
Date
Debt
Jan 1, 2019
109,941.00 AUD
Jan 1, 2020
109,941.00 AUD
Jan 1, 2021
484,370.00 AUD
Jan 1, 2022
304,215.00 AUD
Jan 1, 2023
170,808.00 AUD
Jan 1, 2024
70,672.00 AUD
Jan 1, 2025
69,915.00 AUD
Jan 1, 2026
14,782.00 AUD
The Oncosil Medical Debt history
YEARDebtYoY
14,782.00AUD-78.86%
69,915.00AUD-1.07%
70,672.00AUD-58.62%
170,808.00AUD-43.85%
304,215.00AUD-37.19%
484,370.00AUD+340.57%
109,941.00AUD0.00%
109,941.00AUD—
0.00AUD—
0.00AUD-100.00%
3.26 MAUD-9.42%
3.60 MAUD-17.29%
4.35 MAUD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Oncosil Medical Stock analysis

What does Oncosil Medical do? Oncosil Medical Ltd is an Australian company specializing in the development and distribution of innovative medical products for the treatment of cancer. The company was founded in 2005 and is based in Sydney. The business model of Oncosil Medical is based on research, development, and marketing of products specifically tailored to the needs of cancer patients. The company focuses on developing medical products that aim to improve the effectiveness of radiation therapy and chemotherapy. The core product of Oncosil Medical is the Oncosil implant. It is a small, implantable catheter containing tiny radioactive silicon particles. The implant is directly inserted into the tumor and releases controlled radiation to specifically destroy the tumor. The Oncosil implant is a promising and innovative new treatment option for many cancer patients. It is particularly suitable for patients with locally advanced pancreatic cancer, which is especially difficult to treat. Studies have shown that the Oncosil implant can significantly improve patients' survival rate. Oncosil Medical also provides other products, such as the Microsil transponder. The Microsil transponder is a small implant used in radiation therapy to make the irradiation of the tumor more effective. The transponder is directly inserted into the tumor, allowing medical professionals to precisely target the radiation to the tumor. In addition to developing and marketing innovative medical products, Oncosil Medical also has a research and development department. The company is constantly searching for new cancer treatment methods and works closely with scientists and researchers to develop new technologies. Oncosil Medical operates in several areas. In addition to developing and marketing medical products, the company also offers a training and education program for doctors and medical personnel. The program ensures that all users of Oncosil Medical's products have the necessary skills and knowledge to use the products safely and effectively. The company also has its own regulatory affairs department, which deals with the application for approvals for new products and procedures. This department works closely with authorities and regulatory agencies to ensure that all products from Oncosil Medical comply with applicable regulations and standards. Overall, Oncosil Medical is an innovative and emerging company specializing in the development and marketing of medical products for cancer treatment. With its highly skilled team of scientists, doctors, and qualified professionals, the company stays up to date with the latest research and technology to ensure that its products are always state-of-the-art and provide customers with the best possible treatment option. Oncosil Medical is one of the most popular companies on Eulerpool.

Debt Details

Understanding Oncosil Medical's Debt Structure

Oncosil Medical's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing Oncosil Medical's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to Oncosil Medical’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in Oncosil Medical’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about Oncosil Medical stock

Debt of Oncosil Medical is 14,782.00 AUD in 2026.

Debt of Oncosil Medical changed from 69,915.00 AUD to 14,782.00 AUD, representing a -78.86% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Debt Oncosil Medical since 2006 – with annual values, charts, and detailed analysis.

Debt's AUD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Debt's Oncosil Medical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Oncosil Medical

All Key Metrics — Oncosil Medical